Witnessing the stock’s movement on the chart, on Thursday, Viridian Therapeutics Inc (NASDAQ: VRDN) set off with pace as it heaved 7.76% to $23.06, before settling in for the price of $21.40 at the close. Taking a more long-term approach, VRDN posted a 52-week range of $10.93-$24.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -12.71%. Meanwhile, its Annual Earning per share during the time was 20.35%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 27.08%. This publicly-traded company’s shares outstanding now amounts to $76.36 million, simultaneously with a float of $66.40 million. The organization now has a market capitalization sitting at $1.76 billion. At the time of writing, stock’s 50-day Moving Average stood at $16.81, while the 200-day Moving Average is $16.72.
Viridian Therapeutics Inc (VRDN) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Viridian Therapeutics Inc’s current insider ownership accounts for 13.04%, in contrast to 82.45% institutional ownership. According to the most recent insider trade that took place on Sep 13 ’24, this organization’s Director bought 1,600,000 shares at the rate of 18.75, making the entire transaction reach 30,000,000 in total value, affecting insider ownership by 3,445,813. Preceding that transaction, on Jan 22 ’24, Company’s Director bought 476,190 for 21.00, making the whole transaction’s value amount to 9,999,990. This particular insider is now the holder of 1,839,954 in total.
Viridian Therapeutics Inc (VRDN) Earnings and Revenue Records
Viridian Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 27.08% and is forecasted to reach -4.18 in the upcoming year.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Let’s observe the current performance indicators for Viridian Therapeutics Inc (VRDN). It’s Quick Ratio in the last reported quarter now stands at 23.99. The Stock has managed to achieve an average true range (ATR) of 1.54. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6071.94.
In the same vein, VRDN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.25, a figure that is expected to reach -1.06 in the next quarter, and analysts are predicting that it will be -4.18 at the market close of one year from today.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Going through the that latest performance of [Viridian Therapeutics Inc, VRDN]. Its last 5-days volume of 1.61 million indicated improvement to the volume of 1.14 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 48.61% While, its Average True Range was 1.64.
Raw Stochastic average of Viridian Therapeutics Inc (VRDN) in the period of the previous 100 days is set at 94.03%, which indicates a major rise in contrast to 92.62% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 120.43% that was higher than 73.93% volatility it exhibited in the past 100-days period.
